Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-enhanced Flu Vaccine in CLL
NCT00962715Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2011
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2a and interferon alfa-2a in influenza (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Immunogenicity rate at Month 6. Planned start Apr 2011; status: withdrawn.
02
Drugs
peginterferon alfa-2ainterferon alfa-2a
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00962715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962715.